Name | Mevastatin |
Description | Mevastatin (ML236B) is an HMG-CoA reductase inhibitor that was initially isolated from the mold Pythium ultimum. Mevastatin was the first statin to enter clinical trials. |
In vitro | Mevastatin competitively inhibits HMG-CoA reductase, subsequently reducing cholesterol synthesis in the liver. After 14 days of high-dose treatment, a more than 30% increase in baseline absolute cerebral blood flow was observed. Oral administration of Mevastatin at doses of 5 mg/kg and 20 mg/kg led to reductions in serum cholesterol levels 3 hours post-administration, with the 20 mg/kg dosage decreasing serum cholesterol by approximately 30%. |
In vivo | The bicyclic portion of Mevastatin binds to the active site of coenzyme A. Mevastatin elevates eNOS mRNA and protein levels, reduces infarct size, and ameliorates neurological deficits in a dose- and time-dependent manner. At a concentration of 0.01 pg/mL (26 nM), Mevastatin can reduce cholesterol synthesis by 50% compared with the control group. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 50 mg/mL (128.04 mM) Ethanol : < 1 mg/mL (insoluble or slightly soluble) H2O : < 1 mg/mL (insoluble or slightly soluble)
|
Keywords | BMP-2 | cardiovascular | Apoptosis | inhibit | phosphorylation | lipid-lowering | neuroprotection | EGFR | NF-κB | Statins | Antibiotic | Autophagy | Bacterial | RANKL | HMG-CoA Reductase (HMGCR) | eNOS | Mevastatin | Inhibitor |
Inhibitors Related | Neomycin sulfate | Sulfamethoxazole sodium | Hydroxychloroquine | Guanidine hydrochloride | Doxycycline | Tributyrin | Dimethyl sulfoxide |
Related Compound Libraries | Anti-Tumor Natural Product Library | Terpene Natural Product Library | Bioactive Compound Library | Natural Product Library | Microbial Natural Product Library | Inhibitor Library | Natural Product Library for HTS | Anti-Aging Compound Library | Anti-infective Natural Product Library | Anti-Cancer Active Compound Library |